Evidence map›Paper›PMID 29966326›Full record

ArticleInternational journal of molecular sciences2018

A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.

Matteo Capaia, Ilaria Granata, Mario Guarracino, Andrea Petretto, Elvira Inglese, Carlo Cattrini, Nicoletta Ferrari, Francesco Boccardo, Paola Barboro

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Sex Hormone Receptor Signals in Human Malignancies.International journal of molecular sciences · 2019
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Matteo CapaiaAcademic Unit of Medical Oncology, Ospedale Policlinico San Martino-IRCCS, L.go R. Benzi 10, 16132 Genova, Italy. matteo.capaia@hsanmartino.it.
Ilaria GranataInstitute for High Performance Computing and Networking (ICAR), National Research Council (CNR), Via Pietro Castellino 111, 80131 Napoli, Italy. ilaria.granata@icar.cnr.it.
Mario GuarracinoInstitute for High Performance Computing and Networking (ICAR), National Research Council (CNR), Via Pietro Castellino 111, 80131 Napoli, Italy. mario.guarracino@cnr.it.ORCID 0000-0003-2870-8134
Andrea PetrettoCore Facilities-Proteomics Laboratory, Giannina Gaslini Institute, L.go G. Gaslini 5, 16147 Genova, Italy. AndreaPetretto@gaslini.org.
Elvira IngleseCore Facilities-Proteomics Laboratory, Giannina Gaslini Institute, L.go G. Gaslini 5, 16147 Genova, Italy. elvira.inglese@gmail.com.
Carlo CattriniAcademic Unit of Medical Oncology, Ospedale Policlinico San Martino-IRCCS, L.go R. Benzi 10, 16132 Genova, Italy. carlo.cattrini@gmail.com.
Nicoletta FerrariMolecular Oncology and Angiogenesis, Ospedale Policlinico San Martino-IRCCS, L.go R. Benzi 10, 16132 Genova, Italy. nicoletta.ferrari@hsanmartino.it.ORCID 0000-0002-6027-1035
Francesco BoccardoAcademic Unit of Medical Oncology, Ospedale Policlinico San Martino-IRCCS, L.go R. Benzi 10, 16132 Genova, Italy. fboccardo@unige.it.
Paola BarboroAcademic Unit of Medical Oncology, Ospedale Policlinico San Martino-IRCCS, L.go R. Benzi 10, 16132 Genova, Italy. paola.barboro@hsanmartino.it.ORCID 0000-0001-9074-9290
Ospedale Policlinico San Martino · ITInstitute for High Performance Computing and Networking · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict the clinical responses to improve patient selection for appropriate treatments. The finding that androgen deprivation therapy (ADT) induces alterations in the androgen receptor (AR) transcriptional program by AR coregulators activity in a context-dependent manner, offers the opportunity for identifying signatures discriminating different clinical states of prostate cancer (PCa) progression. Gel electrophoretic analyses combined with western blot showed that, in androgen-dependent PCa and CRPC in vitro models, the subcellular distribution of spliced and serine-phosphorylated heterogeneous nuclear ribonucleoprotein K (hnRNP K) isoforms can be associated with different AR activities. Using mass spectrometry and bioinformatic analyses, we showed that the protein sets of androgen-dependent (LNCaP) and ADT-resistant cell lines (PDB and MDB) co-immunoprecipitated with hnRNP K varied depending on the cell type, unravelling a dynamic relationship between hnRNP K and AR during PCa progression to CRPC. By comparing the interactome of LNCaP, PDB, and MDB cell lines, we identified 51 proteins differentially interacting with hnRNP K, among which KLK3, SORD, SPON2, IMPDH2, ACTN4, ATP1B1, HSPB1, and KHDRBS1 were associated with AR and differentially expressed in normal and tumor human prostate tissues. This hnRNP K⁻AR-related signature, associated with androgen sensitivity and PCa progression, may help clinicians to better manage patients with CRPC.

Indexed as

Cell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHeterogeneous-Nuclear Ribonucleoprotein KHumansImmunoprecipitationMalePhosphorylationProstatic Neoplasms, Castration-ResistantReceptors, AndrogenHeterogeneous-Nuclear Ribonucleoprotein KReceptors, Androgenandrogen deprivation therapyandrogen receptorcastration-resistant prostate cancerheterogeneous nuclear ribonucleoprotein K

Identifiers

PMID29966326
PMCPMC6073607
OpenAlexW2811194446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.